Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Calcified Tissue International
Published in: Calcified Tissue International 6/2009

01-06-2009

Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States

Authors: Bernardo Nuche-Berenguer, Paola Moreno, Pedro Esbrit, Sonia Dapía, José R. Caeiro, Jesús Cancelas, Juan J. Haro-Mora, María L. Villanueva-Peñacarrillo

Published in: Calcified Tissue International | Issue 6/2009

Login to get access

Abstract

It has been suggested that hormones released after nutrient absorption, such as glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 2 (GLP-2), could be responsible for changes in bone resorption. However, information about the role of GLP-1 in this regard is scanty. Diabetes-related bone loss occurs as a consequence of poor control of glucose homeostasis, but the relationship between osteoporosis and type 2 diabetes remains unclear. Since GLP-1 is decreased in the latter condition, we evaluated some bone characteristics in streptozotocin-induced type 2 diabetic (T2D) and fructose-induced insulin-resistant (IR) rat models compared to normal (N) and the effect of GLP-1 or saline (control) treatment (3 days by osmotic pump). Blood was taken before and after treatment for plasma measurements; tibiae and femora were collected for gene expression of bone markers (RT-PCR) and structure (μCT) analysis. Compared to N, plasma glucose and insulin were, respectively, higher and lower in T2D; osteocalcin (OC) and tartrate-resistant alkaline phosphatase 5b were lower; phosphate in IR showed a tendency to be higher; PTH was not different in T2D and IR; all parameters were unchanged after GLP-1 infusion. Bone OC, osteoprotegerin (OPG) and RANKL mRNA were lower in T2D and IR; GLP-1 increased OC and OPG in all groups and RANKL in T2D. Compared to N, trabecular bone parameters showed an increased degree of anisotropy in T2D and IR, which was reduced after GLP-1. These findings show an insulin-independent anabolic effect of GLP-1 and suggest that GLP-1 could be a useful therapeutic agent for improving the deficient bone formation and bone structure associated with glucose intolerance.
Literature
1.
Creutzfeldt W (2001) The entero-insular axis in type 2 diabetes. Incretins as therapeutic agents. Exp Clin Endocrinol Diabetes 109:S288–S303PubMedCrossRef
2.
Valverde I, Morales M, Clemente F, López-Delgado MI, Delgado E, Perea A, Villanueva-Peñacarrillo ML (1994) Glucagon-like peptide-1: a potent glycogenic hormone. FEBS Lett 349:313–316PubMedCrossRef
3.
Villanueva-Peñacarrillo ML, Alcántara A, Clemente F, Delgado E, Valverde I (1994) Potent glycogenic effect of GLP-1 (7–36) amide in rat skeletal muscle. Diabetologia 37:1163–1166PubMedCrossRef
4.
Villanueva-Peñacarrillo ML, Puente J, Redondo A, Clemente F, Valverde I (2001) Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in NIDDM and IDDM rats. Endocrine 15:241–248PubMedCrossRef
5.
Sancho V, Trigo MV, González N, Valverde I, Malaisse WJ, Villanueva-Peñacarrillo ML (2005) Effects of GLP-1 and exendins on kinase activity, 2-deoxy-d-glucose transport, lipolysis and lipogenesis in adipocytes from normal and streptozotocin-induced type 2 diabetic rats. J Mol Endocrinol 35:27–38PubMedCrossRef
6.
Villanueva-Peñacarrillo ML, Delgado E, Trapote MA, Alcántara AI, Clemente F, Luque MA, Perea A, Valverde I (1995) Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 146:183–189PubMedCrossRef
7.
Delgado E, Luque MA, Alcántara A, Trapote MA, Clemente F, Galera C, Valverde I, Villanueva-Peñacarrillo ML (1995) Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 16:225–229PubMedCrossRef
8.
Yang H, Egan JM, Wang Y, Moyes D, Roth J, Montrose MH, Montrose-Rafizadeh C (1998) GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Am J Physiol 275:675–683
9.
Thorens B (1992) Expression clonning of the pancreatic beta-cell receptor for the gluco-incretin hormone glucagon-like peptide-1. Proc Natl Acad Sci USA 89:8641–8645PubMedCrossRef
10.
Ruiz-Grande C, Alarcón C, Mérida E, Valverde I (1992) Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Peptides 13:13–16PubMedCrossRef
11.
Villanueva-Peñacarrillo ML, Márquez L, González N, Díaz-Miguel M, Valverde I (2001) Effect of GLP-1 on lipid metabolism in human adipocytes. Horm Metab Res 33:73–77PubMedCrossRef
12.
Márquez L, Trapote MA, Luque MA, Valverde I, Villanueva-Peñacarrilo ML (1998) Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide 1(7–36) amide on rat liver and adipose tissue. Cell Biochem Funct 16:51–56PubMedCrossRef
13.
Redondo A, Trigo V, Acitores A, Valverde I, Villanueva-Peñacarrillo ML (2003) Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204:43–50PubMedCrossRef
14.
Acitores A, González N, Sancho V, Valverde I, Villanueva-Peñacarrillo ML (2004) Cell signalling of the glucagón-like peptide 1 action in rat skeletal muscle. J Endocrinol 180:389–398PubMedCrossRef
15.
Larsen PJ, Holst JJ (2005) Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter. Regul Pept 15:97–107CrossRef
16.
Nikolaidis JA, Mankas S, Sokos GG, MIska G, Shah A, Elahi D, Shannon RP (2004) Effects of glucagon-like peptide in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109:962–965PubMedCrossRef
17.
Inzerillo A, Epstein S (2004) Osteoporosis and diabetes mellitus. Rev Endocrine Metab Disord 5:261–268CrossRef
18.
Clowes JA, Khosla S, Eastell R (2005) Perspective potential role of pancreatic and enteric hormones in regulating bone turnover. J Bone Miner Res 9:1497–1506CrossRef
19.
Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, Byrjalsen I, Krarup T, Holst JJ, Christiansen C (2003) Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 18:2180–2189PubMedCrossRef
20.
Bollag RJ, Zhong Q, Phillips P, Min L, Zhong L, Cameron R, Mulloy AL, Rasmussen H, Qin F, Ding KH, Isales CM (2000) Osteoblasts-derived cells express functional glucose-dependent insulinotropic peptide receptors. Endocrinology 141:1228–1235PubMedCrossRef
21.
Xie D, Zhong Q, Ding KH, Cheng H, Williams S, Correa D, Bollag WB, Bollag RJ, Insogna K, Troiano N, Coady C, Hamrick M, Isales CM (2007) Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. Bone 40:1352–1360PubMedCrossRef
22.
Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, Tanaka K, Drucker DJ, Seino Y, Inagaki N (2008) The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. Endocrinology 149:574–579PubMedCrossRef
23.
Levin ME, Boisseau VC, Avioli LV (1976) Effects of diabetes mellitus on bone mass in juvenile adult-onset diabetes. N Engl J Med 294:241–245PubMed
24.
Pl VanDaele, Stolk RP, Burguer H, Algra D, Grobee DE, Hofman A, Birkenhäger JC, Pols HA (1995) Bone density in non-insulin-dependent diabetes mellitus: the Rotterdam study. Ann Intern Med 122:409–414
25.
Hirano Y, Kishimoto H, Hagino H, Teshima R (1999) The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. J Bone Miner Metab 17:119–124PubMedCrossRef
26.
Portha B, Picon L, Rosselin G (1979) Chemical diabetes in the adult rat as the spontaneous evolution of neonatal diabetes. Diabetologia 17:371–377PubMedCrossRef
27.
Iwase M, Kikuchi M, Nunoi K, Wakisaka M, Maki Y, Sadoshima S, Fujishima M (1987) Blood pressure changes in spontaneously hypertensive and normotensive rats with neonatal streptozotocin induced type 2 diabetes. Clin Exp Hypertens A 9:2157–2168PubMedCrossRef
28.
Cancelas J, Prieto PG, García-Arévalo M, Villanueva-Peñacarrillo ML, Malaisse WJ, Valverde I (2008) Induction and reversibility of insulin resistance in rats exposed to exogenous d-fructose. Horm Metab Res 40:459–466PubMedCrossRef
29.
Arnés L, González N, Tornero-Esteban P, Sancho V, Acitores A, Valverde I, Delgado E, Villanueva-Peñacarrillo ML (2008) Characteristics of GLP-1 and exendin action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle. Int J Mol Med 22:127–132PubMed
30.
Herbert V, Lau KS, Goltlieb CW, Bleicher SJ (1956) Coated charcoal inmunoassay of insulin. J Clin Invest 25:1375–1384
31.
Valverde I, Barreto M, Malaisse WJ (1988) Stimulation by d-glucose of protein biosynthesis in tumoral insulin-producing cells (RINm5F line). Endocrinology 122:1443–1448PubMedCrossRef
32.
Ascencio C, Torres N, Isoard-Acosta F, Gómez-Pérez FJ, Hernández-Pando R, Tovar AR (2004) Soy protein affects serum insulin and hepatic SREBP-1 mRNA and reduces fatty liver in rats. J Nutr 134:522–529PubMed
33.
Feldkamp LA, Davis LC, Kress JW (1984) Practical cone-beam algorithm. J Opt Soc Am A 1:612–619CrossRef
34.
Hildebrand T, Ruegsegger P (1997) A new method for the model-independent assessment of thickness in three-dimensional images. J Microsc 185:67–75CrossRef
35.
Ulrich D, Van RB, Laib A, Ruegsegger P (1999) The ability of three-dimensional structural indices to reflect mechanical aspects of trabecular bone. Bone 25:55–60PubMedCrossRef
36.
Hildebrand T, Ruegsegger P (1997) Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1:15–23PubMedCrossRef
37.
Harrigan TP, Mann RW (1984) Characterisation of microstructural anisotropy in orthotropic materials using a second rank tensor. J Mater Sci 19:761–767CrossRef
38.
Hahn M, Vogel M, Pompesius-Kempa M, Delling G (1992) Trabecular bone pattern factor a new parameter for simple quantification of bone microarchitecture. Bone 13:327–330PubMedCrossRef
39.
Carnevale V, Romagnoli E, D′Erasmo E (2004) Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev 20:196–204PubMedCrossRef
40.
Hampson G, Evans C, Petitt RJ, Evans WD, Woodhead SJ, Peters JR, Ralston SH (1998) Bone mineral density, collagen type 1 alpha genotypes and bone turnover in premenopausal women with diabetes mellitus. Diabetologia 41:1314–1320PubMedCrossRef
41.
Hofbauer L, Brueck CC, Singh SK, Dobnig H (2007) Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 22:1317–1328PubMedCrossRef
42.
Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C (2002) Mechanism of circadian variation in bone resorption. Bone 30:307–313PubMedCrossRef
43.
Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R (2002) Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886–890PubMedCrossRef
44.
Clowes JA, Robinson RT, Heller SR, Eastell R, Blumsohn A (2002) Acute changes of bone turnover and PTH induced by insulin and glucose: euglucemic and hypoglycemic hyperinsulinemic clamp studies. J Clin Endocrinol Metab 87:3324–3329PubMedCrossRef
45.
Ding KH, Shi XM, Zhong Q, Kang B, Xie D, Bollag WB, Bollag RJ, Hill W, Washington W, Mi QS, Insogna K, Chutkan N, Hamrick M, Isales CM (2008) Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J Bone Miner Res 23:536–543PubMedCrossRef
46.
Henriksen DB, Alexandersen P, Hartmann B, Adrian CL, Byrjalsen I, Bone HG, Holst JJ, Christiansen C (2007) Disassociation of bone resorption and formation by GLP-2 a 14-day study in healthy postmenopausal women. Bone 40:723–729PubMedCrossRef
47.
Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001) Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 30:609–613CrossRef
48.
Thrailkill KM, Liu L, Wahl EC, Bunn RC, Perrien DS, Cockrell GE, Skinner RA, Hogue WR, Carver AA, Fowlkes JL, Aronson J, Lumpkin CK Jr (2005) Bone formation is impaired in a model of type 1 diabetes. Diabetes 54:2875–2881PubMedCrossRef
49.
Saito M, Fujii K, Marumo K (2006) Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 17:1514–1523PubMedCrossRef
50.
Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, Holst JJ (2004) Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 34:140–147PubMedCrossRef
51.
Power RA, Iwaniec UT, Magee KA, Mitova-Caneva NG, Wronski TJ (2004) Basic fibroblast growth factor has rapid bone anabolic effects in ovariectomized rats. Osteoporos Int 15:716–723PubMedCrossRef
Metadata
Title
Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States
Authors
Bernardo Nuche-Berenguer
Paola Moreno
Pedro Esbrit
Sonia Dapía
José R. Caeiro
Jesús Cancelas
Juan J. Haro-Mora
María L. Villanueva-Peñacarrillo
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
Calcified Tissue International / Issue 6/2009
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-009-9220-3

Other articles of this Issue 6/2009

Calcified Tissue International 6/2009 Go to the issue

OriginalPaper

Binge Alcohol-Induced Bone Damage is Accompanied by Differential Expression of Bone Remodeling-Related Genes in Rat Vertebral Bone

OriginalPaper

Hypothalamic Suppression Decreases Bone Strength Before and After Puberty in a Rat Model

OriginalPaper

Surface Aggregation of Urinary Proteins and Aspartic Acid-Rich Peptides on the Faces of Calcium Oxalate Monohydrate Investigated by In Situ Force Microscopy

OriginalPaper

Bone Histomorphometry in Male Idiopathic Osteoporosis

OriginalPaper

Isokinetic Resistance Training Increases Tibial Bending Stiffness in Young Women

OriginalPaper

Association of a RUNX2 Promoter Polymorphism with Bone Mineral Density in Postmenopausal Korean Women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits